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ABSTRACT
Background and the purpose of the study: Diclofenac sodium is a non-steroidal anti-inflammatory 
agent with a short biological half-life (1-2 hr) and requires multiple dosing. This research was 
carried out to develop and optimize diclofenac sodium loaded alginate-PVP K 30 microbeads to 
eliminate the need for multiple dosing and adverse effects.
Methods: Diclofenac sodium loaded alginate-PVP K 30 microbeads were prepared by ionotropic 
gelation. Particle size, drug release, swelling, FTIR and SEM  analyses  were performed.
Results: Optimized microbeads showed particle size of 0.589 ± 0.054 to 0.620 ± 0.067 mm, and 
drug entrapment efficiency of 97.88 ± 2.86 to 98.60 ± 3.55 %. The in vitro drug release from 
microbeads was sustained over 10 hrs and followed controlled-release pattern. FTIR analysis 
indicated the possibility of intermolecular hydrogen bonding interactions, i.e., –OH…O=C in 
microbeads.
Conclusion: Microbeads for oral controlled delivery of diclofenac sodium were successfully 
developed by ionotropic gelation.
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INTRODUCTION
Alginate, the monovalent form of alginic acid, belong 
to the family of linear copolymers composed of β-D- 
mannuronic  acid  monomers  (M),  regions  of  ∞-L- 
guluronic acid residues (G), and regions of interspersed 
M and G units (1). It is used as matrix material in 
various formulations due to its hydrogel-forming 
properties (2). Alginates undergo gelation due to ionic 
interaction between carboxylic acid groups located 
on polymer backbone and these cations like Ca2+, 
Al3+, etc (3-4). Various drugs have been successfully 
incorporated in alginate hydrogels and have exhibited 
different drug release profiles (1, 4-6). 
Diclofenac sodium (DS) is a non-steroidal anti-
inflammatory agent widely used as analgesic (7). Its 
biological half-life is 1-2 hr (2) and requires multiple 
dosing to maintain therapeutic concentration in 
blood. Hence, the controlled release systems of DS 
can eliminate the need for multiple dosing and adverse 
effects. Several investigations on formulation of DS-
loaded alginate-based microparticles/beads using 
different polymer-blend have been reported (7-10). 
However, no attempt has been taken to formulate 
DS-loaded bead system using alginate-polyvinyl 
pyrrolidone (PVP) blend. Therefore in the present 
investigation, an attempt was made to develope and 
optimize DS-loaded alginate-PVP K 30 microbeads. 
The effects of ratios of sodium alginate to PVP K 
30 and CaCl2 (cross-linker) concentrations on drug 
entrapment and release were analyzed using central 
composite design (CCD). 
MATERIAL AND METHODS
Materials
DS (Techno Remedies, India), calcium chloride, 
sodium alginate and PVP K 30 (Loba Chemie, India) 
were used in this study. Other chemicals used were 
of analytical grades.
Microbead preparation
DS-loaded alginate-PVP K 30 microbeads were 
prepared by ionotropic gelation (2). Sodium alginate 
and PVP K 30 aqueous solutions were mixed 
together. Then, DS was added to the mixture and 
homogenized (for 10 min, 1000 rpm). The resulting 
mixture (drug : polymer = 1:2) was dropped into 
CaCl2 solution via 26-gauge needle.  After 15 
min, beads were collected by decantation, washed 
repeatedly with deionized water and dried at 45°C 
356for 12 hrs. 
DS-loaded alginate microbeads were prepared by 
the same method but without addition of PVP K 30. 
Experimental design 
The experimental factors were selected as polymer-
blend ratio and CaCl2 concentration; while responses 
were Drug Entrapment Efficiency (DEE) and drug 
release after 10 hrs (R10hr). The factors and levels are 
reported in table 1. The quadratic model was used to 
evaluate responses using Design-Expert® Software 
according to CCD (11):
Y=b0+b1X1+b2X2+b3X1X2+b4X1
2+b5X2
2                        (1)
 
where, Y = response; b0 = intercept, and  b1-b5 = 
regression  coefficients.  X1  and  X2 = individual 
effects;  X1
2  and  X2
2  =  quadratic  effects;  X1X2 = 
interaction effect. 
Determination of the Drug 
Entrapment Efficiency (DEE)
Drug-loaded microbeads (100 mg) were dispersed in 
500 ml of phosphate buffer of pH 7.4 and sonicated 
for 10 min. The mixture was stirred at 1000 rpm for 4 
hrs and filtered through Whatman® filter paper. Drug 
contents in filtrates were determined using UV-VIS 
spectrophotometer (Shimadzu, Japan) at 276 nm 
wavelength. The DEE of beads was calculated using 
following formula:
DEE (%) =
Actual drug content
× 100    (2)
  Theoretical drug content
Particle size and morphological analyses
Microbeads were measured for particle size using 
optical microscope (Olympus, Japan). Surface 
morphology was examined by scanning electron 
microscopy (SEM) (Hitachi, Japan).
Fourier transform infrared (FTIR) spectroscopy 
Spectra were obtained by FTIR spectrophotometer 
(Perkin-Elmer, USA) in the wavelength region of 
4000-400 cm-1 using pellets of KBr.
 In vitro drug release studies 
Dissolution apparatus USP (Campbell Electronics, 
India) was employed to study the drug release 
at 37°C 50 rpm. Microbeads containing DS 
equivalent to 100 mg were taken in 900 ml of 
dissolution medium (0.1 N HCl of pH 1.2 for 2 hrs 
and phosphate buffer of pH 7.4 for next hrs). Drug 
content in samples were measured using UV-VIS 
spectrophotometer (Shimadzu, Japan) at 276 nm 
wavelength.
Swelling evaluation
Microbeads (100 mg) were soaked in phosphate 
buffer of pH 7.4 and 0.1 N HCl of pH 1.2. Swelled 
microbeads were removed and weighed. Swelling 
indexes were determined using the formula:
Swelling index =
Weight of swelled  
microbeads Dry weight 
 ×100   (3) 
 Dry weight 
RESULTS AND DISCUSSION
DS-loaded alginate-PVP K 30 microbeads were 
prepared by ionotropic gelation according to CCD 
(Table 2). Quadratic models were selected as better-
fit models due to smaller PRESS, and insignificant 
lack of fit (Table 3). Results of ANOVA indicated 
all  models  were  significant  (Table  4).  After 
eliminating non-significant (p > 0.05) terms, the 
models became:
DEE =58.67-0.66 X 1+ 8.12 X2 - 1.28 X1
2 - 0.41 X2
2           (4)
R10h =99.43-1.13X 1 -3.54 X2 -0.40 X1X2 - 0.06 X2
           
  (5)
Three-dimensional response surface (Fig. 1), and 
contour plots (Fig. 2) demonstrate changes in DEE, 
and R10hr due to variation of factors. For optimization, 
numerical analysis was performed by restricting 
desirable ranges to 95 ≤ DEE ≤ 100 %, and 60 ≤     
R10hr ≤ 65 %. The optimized microbeads
were formulated and evaluated (Table 5). Models to 
produce optimized responses were well fitted (R2 = 
0.9912 for DEE, and 0.9967 for R10hr). 
Optimized microbeads showed DEE of 97.88 ± 
2.86 to 98.60 ± 3.55 %. Among DS-loaded alginate 
microbeads, highest DEE of 85.77 ± 2.92 % was 
observed in the case of S-3 (Table 6). 
The particle sizes of alginate-PVP K 30 microbeads 
decreased by increase in the amount of incorporated 
PVP K 30 (due to decrease in viscosity and 
droplet sizes of polymer solution), and the CaCl2 
concentration (due to high degree cross-linking) 
(Table 7). The surface morphology of optimized 
beads was visualized by SEM, which showed rough 
surface (Fig. 3).
In FTIR spectra, incorporation of DS in alginate 
showed characteristic peaks of DS, and alginate 
(Fig. 4). However, in DS-loaded alginate-PVP K 
30 microbeads, two characteristic shifts for C=O 
stretching of PVP, and –OH groups of alginate 
compared to pure component (Fig. 4) appeared 
which strongly supports the idea of an intermolecular 
hydrogen-bonding between C=O groups of PVP, 
and –OH groups of alginate in alginate-PVP K 30 
microbeads. 
Microbeads were found to release negligible 
amounts of DS in acidic medium which probably 
could be the surface adhered drug. Alginate-
PVP K 30 microbeads showed prolonged drug 
release over 10 hrs (Figs. 5and 6). In contrast, 
357Development of diclofenac sodium-loaded alginate-PVP K 30 microbeads 358
Normalized levels
         Experimental Settings
SA:PVP K 30a
(X1)
CaCl2 (% w/v)
(X2)
- 1.414 1.00 1.00
- 1 1.50 2.50
0  2.80 6.30
1 4.00 10.00
1.414 4.50 11.60
a SA:PVP K 30 = Sodium alginate to polyvinyl pyrrolidone K 30 ratio
Table 1. Factors and levels of the circumscribed central composite design.
Experimental
formulations
Normalized levels of factors Responsesa
SA:PVP K30b
(X1)
CaCl2 (% w/v)
(X2)
DEE (%)c R10hr (%)d
SP-1 -1 -1 75.32 ± 2.14 94.44 ± 3.45
SP-2 -1 1 98.77 ± 2.76 66.32 ± 1.08
SP-3 1 -1 60.33 ± 1.64 99.56 ± 3.45
SP-4 1 1 87.87 ± 2.23 78.92 ± 2.40
SP-5 -1.414 0 94.82 ± 3.42 77.98 ± 2.33
SP-6 1.414 0 77.68 ± 1.96 92.36 ± 3.02
SP-7 0 -1.414 58.59 ± 1.12 99.64 ± 3.42
SP-8 0 1.414 98.88 ± 2.25 67.31 ± 1.88
SP-9 0 0 89.35 ± 2.16 85.87 ± 2.43
SP-10 0 0 88.82 ± 2.07 85.07 ± 2.11
SP-11 0 0 89.20 ± 2.96 85.22 ± 2.40
SP-12 0 0 90.63 ± 2.88 85.22 ± 2.23
SP-13 0 0 88.43 ± 2.13 84.95 ± 2.17
a Observed response values: Mean ± SD (n = 3); b SA:PVP K30 = Sodium alginate to polyvinyl pyrrolidone K 30 ratio; c DEE =  Drug 
entrapment efficiency (%); d R10hr =  % Drug released in 10 hrs
Table 2. Experimental plan and observed response values from randomized run in central composite design.
alginate microbeads showed high percent of DS 
release (Fig. 6). The drug release from optimized 
microbeads was evaluated using various kinetic 
models, and it was found that the drug release 
followed zero-order model (Table 8), indicating 
controlled-release pattern. The Korsmeyer-Peppas 
model was employed to distinguish Fickian-release 
when n ≤ 0.43 and case-II transport when n ≥ 0.85 
(in Korsmeyer-Peppas Model, n is diffusional 
exponent) (12, 13). The values of n ranged between 
0.9632 to 0.9950 (Table 8), indicating the drug 
release followed case-II transport. 
The swelling of optimized DS-loaded alginate-
PVP K 30 microbeads was lower in acidic 
medium (pH 1.2) in comparison with that of 
alkaline medium (pH 7.4) (Fig. 7). Maximum 
swelling was noticed after 2-3 hrs in alkaline pH 
after which, erosion and dissolution took place. 
The swelling of optimized microbeads in alkaline 
pH could be explained by the exchange of ions   
between the calcium ion of microbeads and the 
sodium ions present in phosphate buffer, under 
influence of calcium-sequestrant phosphate ions, 
which could result in disaggregation of alginate-
PVP K 30-matrix structure leading to matrix 
erosion and dissolution of swollen microbeads 
(14, 15). 
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Source Sum of squares Degree of freedom Mean square F value p-value Prob > F
(A) For DEE (%)a 
Model 2016.91 5 403.38 188.70 < 0.0001
X1 314.12 1 314.12 146.94 < 0.0001
X2 1457.15 1 1457.15 681.64 < 0.0001
X1X2 4.18 1 4.18 1.96 0.2046
X1
2
27.77 1 27.77 12.99 0.0087
X2
2
230.44 1 230.44 107.80 < 0.0001
(B) For R10hr (%)b
Model 1315.43 5 263.09 612.17 < 0.0001
X1 181.04 1 181.04 421.25 < 0.0001
X2 1115.84 1 1115.84 2596.44 <0.0001 
X1X2 13.99 1 13.99 32.55 0.0007
X1
2
0.02 1 0.02 0.05 0.8376
X2
2
4.3 1 4.39 10.22 0.0151
DEE = Drug entrapment efficiency (%); R10hr =  % Drug released in 10 hrs.
X1 and X2 represent the factors; X1
2 and X2
2 are the quadratic effect; X1X2 is the interaction effect.
Table 4. Summary of ANOVA for the response parameters.
Source 
                                   DEE (%)                                                           R10hr (%) 
Sum of squares p-value Sum of squares p -value
(a) Model analysis
Mean vs Total 92855.36 93597.19
Linear vs Mean 1771.28 < 0.0001 1296.88 < 0.0001
2FIc vs Linear 4.18 0.7105 13.99 0.0028
Quadratic vs 2FI 241.45 < 0.0001 4.57 0.0395
Cubic vs Quadratic 4.82 0.3780 2.01 0.0635
Residual 10.14 1.00
Total 94887.24 94915.63
(b) Lack of fit
Linear 257.83 0.0007 21.04 0.0034
2FI 253.65 0.0005 7.05 0.0195
Quadratic 12.20 0.0600 2.49 0.0533
Cubic 7.37 0.0310 0.48 0.1293
Pure error 2.77 0.52
(c ) R2 analysis
            Adjusted                                  Predicted                                Adjusted                               Predicted    
R2 R2 R2 PRESSd R2 R2 R2 PRESSd
Linear 0.8717 0.8461 0.7762 454.69 0.9836 0.9804 0.9651 45.98
2FI 0.8738 0.8317 0.6734 663.68 0.9943 0.9923 0.9860 18.52
Quadratic 0.9926 0.9874 0.9552 91.05 0.9977 0.9961 0.9860 18.49
Cubic 0.9950 0.9880 0.7656 476.18 0.9992 0.9982 0.9763 31.24                   
Table 3. Summary of the model analysis (A), lack of fit (B), and R2 analysis (C) for the measured responses.
aDEE = Drug entrapment efficiency(%); b R10hr =  % Drug released in 10 hrs; c2FI = Two factor interaction; dPRESS  = predicted residual 
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Trial Code
Factors Responses
 SA:PVP K 30a CaCl2 (% w/v)
DEE (%)b R10hr (%)c 
Predicted Observedd Predicted Observedd  
 O-1 1.00 8.60 99.45 98.27 ± 3.42 69.55 71.28 ± 2.22  
 O-2 1.50 9.20 99.79 98.60 ± 3.55 69.41 71.02 ± 2.67
 O-1 2.20 10.30 99.16 97.88 ± 2.86 68.46 69.88 ± 2.82   
aSA:PVP K 30 = Sodium alginate to polyvinyl pyrrolidone K 30 ratio; bDEE=Drug entrapment efficiency (%); cR10hr= % Drug released 
within 10 hrs; dObserved response values: Mean ± SD (n = 3).
Table 5. Results of experiments for confirmation of the optimization capability.
Trial Code
Processing parameters Responsesa
SAb CaCl2 (% w/v) DEE (%)c R10 hr (%)d 
 S-1 2.00 8.60 78.23 ± 2.06 95.38 ± 3.62  
 S-2 2.00 9.20 81.48 ± 3.15 91.22 ± 3.23
 S-1 2.00 10.30 85.77 ± 2.92 81.03 ± 3.05   
aObserved response values: Mean ± SD (n = 3); bSA = Sodium alginate; cDEE =  Drug entrapment efficiency (%); dR10hr =  % Drug 
released in 10 hrs
Table 6. Processing parameters and responses of plain alginate microbeads containing diclofenac sodium. 
Formulation codesa Average diameter (mm)b
SP-1 0.93 ± 0.08
SP-2 0.59 ± 0.07
SP-3 0.95 ± 0.10
SP-4 0.84 ± 0.07
SP-5 0.79 ± 0.05
SP-6 0.87 ± 0.09
SP-7 0.97 ± 0.07
SP-8 0.60 ± 0.06
SP-9 0.86 ± 0.08
SP-10 0.86 ± 0.10
SP-11 0.86 ± 0.08
SP-12 0.84 ± 0.06
SP-13 0.85 ± 0.09
O-1 0.59 ± 0.05
O-2 0.62 ± 0.08
O-3 0.62 ± 0.07
S-1 0.87 ± 0.07
S-2 0.83 ± 0.08
S-3 0.82 ± 0.08
aSP-1 to O-3 were alginate-PVP K 30 microbeads; whereas 
S-1-S-3 were plain alginate microbeads containing diclofenac 
sodium. bMean ± SD (n = 3)
Table 7. Average diameter of alginate-PVP K 30 and plain 
alginate microbeads containing diclofenac sodium, measured by 
optical microscopic method.
microbeads containing DS was developed based on 
central composite design. The DEE of optimized 
alginate-PVP K 30 microbeads containing DS were 
found to be 97.88 ± 2.86 to 98.60 ± 3.55 % with a 
controlled-release pattern (zero-order) and case-II 
transport drug release. The swelling behaviour of 
the  developed microbeads was influenced by the 
pH of the test medium. The FTIR spectroscopy 
showed an intermolecular hydrogen-bonding which 
could be formed between C=O groups of PVP K 
30 and –OH groups of alginate in alginate-PVP K 
30 microbeads which might sustaine drug release 
from alginate-PVP K 30 microbeads and minimize 
drug leaching during preparation to facilitate 
increase in DEE. The methods of preparation 
of DS-loaded alginate-PVP K 30 for controlled 
release characteristics were found to be simple and 
reproducible. In conclusion, an oral alginate-PVP 
K 30 microbeads for controlled delivery system of 
DS was successfully developed by alginate-PVP K 
30 blending using ionotropic gelation. 
ACKNOWLEDGEMENTS
Authors are appreciated for the great help of the 
Principal and Management of Seemanta Institute 
of Pharmaceutical Sciences, Jharpokharia, India for 
proving research facilities. Nayak et al / DARU 2011 19 (5) 356-366 361
FIGURES 
(a) 
(b) 
Figure 1. Effects of experimental factors presented by response surface plots (a, b).
Formulation codes O-1 O-2 O-3
Zero-order Model
Ko 0.0711 0.0705 0.0730
R2 0.9962 0.9937 0.9960
First-order Model
K1st 0.1426 0.1394 0.1427
R2 0.9795 0.9736 0.9602
Higuchi Model
KH 0.3486 0.3456 0.3579
R2 0.9870 0.9825 0.9845
Korsmeyer-Peppas KP 0.0779 0.0724 0.0728
Model
n 0.9632 0.9884 0.9950
R2 0.9955 0.9871 0.9952
Table 8. Results of curve fitting of the in-vitro diclofenac sodium release data from different optimized alginate-PVP K30 microbeads.
FIGURES 
(a) 
(b) 
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Figure 2. Effect of main effects on responses presented by contour plots (a, and b).
Figure 1. Effects of experimental factors presented by response surface plots (a, b) 
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Figure 1. Effects of experimental factors presented by response surface plots (a, b) 
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Figure 2. Effect of main effects on responses presented by contour plots (a, and b) Nayak et al / DARU 2011 19 (5) 356-366 363
Figure 3. Photomicrograph of the surface morphology of DS-loaded alginate-PVP K 30 
microbead (O-2) 
Figure 3. Photomicrograph of the surface morphology of DS-loaded alginate-PVP K 30 microbead (O-2).
Figure 4. FTIR spectra of DS, sodium alginate, PVP K 30, DS-loaded alginate (S-3) and DS-loaded alginate-PVP K 30 microbeads             
(O-2).
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Figure 5. (a). In vitro drug release from alginate-PVP K 30 microbeads containing DS (SP-1 to SP-6) (Mean ± SD, n = 3). (b). In vitro 
drug release from alginate-PVP K30 microbeads containing DS (SP-7 to SP-13) (Mean ± SD, n = 3)
Figure 5. (a). In vitro drug release from alginate-PVP K 30 microbeads containing DS (SP-1 
to SP-6) [Mean ± SD, n = 3] 
(b). In vitro drug release from alginate-PVP K30 microbeads containing DS (SP-7 to SP-13) 
[Mean ± SD, n = 3]
Figure 6. In vitro drug release from optimized alginate-PVP K 30 microbeads (O-1 to O-3) 
and alginate microbeads (S-1 to S-3) containing DS [Mean ± SD, n = 3]
Figure 6. In vitro drug release from optimized alginate-PVP K 30 microbeads (O-1 to O-3) and alginate microbeads (S-1 to S-3) contain-
ing DS (Mean ± SD, n = 3).Nayak et al / DARU 2011 19 (5) 356-366 365
Figure 7. Swelling behavior of the optimized alginate-PVP K 30 microbeads containing DS 
in pH 1.2 and pH 7.4. [Mean ± SD, n = 3]
Figure 7. Swelling behavior of the optimized alginate-PVP K 30 microbeads containing DS in pH 1.2 and pH 7.4. (Mean ± SD, n = 3).
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